Education
About Us
Working with TipRanks
Follow Us
Inventiva (IVA)
NASDAQ:IVA
Earnings Data
Report Date
Sep 25, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.63Last Year’s EPS
-0.87Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 26, 2025
|% Change Since: 2.08%
|Next Earnings Date:Sep 25, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in the clinical development of lanifibranor, positive trial results, and a strong financial position bolstered by recent financing activities. However, challenges such as workforce reduction and decreased revenue were noted. The sentiment remains cautiously optimistic with strategic partnerships and governance strengthening, despite financial and operational challenges.Company Guidance
During the Inventiva Full Year 2024 Financial Results Webcast and Conference Call, key guidance and metrics were provided by the company's leadership. CEO Frédéric Cren highlighted the significant progress in the clinical development of lanifibranor, emphasizing the closing of screening for the Phase 3 NATiV3 trial and targeting recruitment completion in H1 2025. The topline results are expected in the second half of 2026, with potential U.S. approval by March. The call also addressed the company's financial position, with a cash runway extending to September 2025, and potentially September 2026 after securing additional financing. The 2024 financial highlights included a cash position of €96.6 million, revenues of €9.2 million, and a net loss of €184.2 million. The company also discussed strategic decisions, such as focusing resources on lanifibranor development, which led to a reduction in workforce by approximately 50%. The call concluded with a discussion on potential partnerships and long-term plans for commercialization.Significant Progress in Lanifibranor Clinical Development
Completed screening of Phase 3 NATiV3 trial in early January 2025, targeting recruitment completion in H1 2025. Three data monitoring committee meetings with positive recommendations for continuation without protocol modification.
Positive Results from LEGEND Trial
Statistically significant reduction in HBA1C with lanifibranor alone and in combination, improved insulin sensitivity, and significant improvement in markers of liver injury. Combination with empagliflozin mitigates weight gain.
Strong Financial Position
Raised approximately $184 million in gross proceeds from several financing operations, including a $125 million structured financing. Cash position at the end of 2024 was €96.6 million, a net positive variance of close to €61 million from the previous year.
Strategic Partnerships and Market Expansion
Partner Hepalys launched clinical development of lanifibranor in Japan. Licensing agreements in place in Japan, South Korea, and China position lanifibranor as a leading oral drug in MASH in these regions.
Strengthened Governance and Team
Reinforced Board of Directors with three new members, including Mark Pruzanski as Chairman. Reinforced development team to prepare for regulatory filing and potential commercial launch of lanifibranor.
---
IVA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
IVA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 26, 2025 | $2.88 | $3.04 | +5.56% |
| Sep 25, 2024 | $2.16 | $1.79 | -17.13% |
| Mar 27, 2024 | $3.82 | $3.62 | -5.24% |
| Sep 28, 2023 | $4.26 | $4.20 | -1.41% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Inventiva (IVA) report earnings?
Inventiva (IVA) is schdueled to report earning on Sep 25, 2025, TBA Not Confirmed.
What is Inventiva (IVA) earnings time?
Inventiva (IVA) earnings time is at Sep 25, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is IVA EPS forecast?
IVA EPS forecast for the fiscal quarter 2025 (Q2) is -0.63.
---